Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BEAM Beam Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: BEAM
Price (delayed)
$17.41
Market cap
$1.75B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.61
Enterprise value
$1.37B
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a
Highlights
BEAM's quick ratio has surged by 84% since the previous quarter and by 47% year-on-year
BEAM's equity has surged by 53% since the previous quarter and by 23% year-on-year
The EPS has dropped by 188% year-on-year
The net income has dropped by 187% year-on-year and by 2.8% since the previous quarter
Key stats
What are the main financial stats of BEAM
Market
Valuations
Earnings
Shares outstanding
100.56M
Market cap
$1.75B
Enterprise value
$1.37B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.3
Price to sales (P/S)
24.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.62
Revenue
$63.58M
Gross profit
$63.58M
Operating income
-$430.72M
Net income
-$387.34M
EBIT
-$387.3M
EBITDA
-$355.61M
Free cash flow
-$360.96M
Per share
Balance sheet
Liquidity
EPS
-$4.61
EPS diluted
-$4.61
Free cash flow per share
-$4.1
Book value per share
$13.42
Revenue per share
$0.72
TBVPS
$16.67
Total assets
$1.47B
Total liabilities
$343.78M
Debt
$158.13M
Equity
$1.12B
Working capital
$1.11B
Debt to equity
0.14
Current ratio
8.81
Quick ratio
8.67
Net debt/EBITDA
1.06
Margins
Efficiency
Dividend
EBITDA margin
-559.3%
Gross margin
100%
Net margin
-609.2%
Operating margin
-677.5%
Return on assets
-31%
Return on equity
-44.2%
Return on invested capital
-42.8%
Return on capital employed
-29.2%
Return on sales
-609.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BEAM stock price
How has the Beam Therapeutics stock price performed over time
Intraday
0.93%
1 week
-13.98%
1 month
6.35%
1 year
-22.76%
YTD
-29.8%
QTD
-10.86%
Financial performance
How have Beam Therapeutics's revenue and profit performed over time
Revenue
$63.58M
Gross profit
$63.58M
Operating income
-$430.72M
Net income
-$387.34M
Gross margin
100%
Net margin
-609.2%
The net income has dropped by 187% year-on-year and by 2.8% since the previous quarter
Beam Therapeutics's operating income has shrunk by 137% YoY and by 3.6% QoQ
Beam Therapeutics's revenue has plunged by 82% YoY
BEAM's gross profit has dropped by 82% year-on-year
Price vs fundamentals
How does BEAM's price correlate with its fundamentals
Growth
What is Beam Therapeutics's growth rate over time
Valuation
What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
1.3
P/S
24.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.62
The EPS has dropped by 188% year-on-year
The price to book (P/B) is 76% lower than the 5-year quarterly average of 5.5 and 43% lower than the last 4 quarters average of 2.3
BEAM's equity has surged by 53% since the previous quarter and by 23% year-on-year
BEAM's price to sales (P/S) is 100% lower than its 5-year quarterly average of 40514.6 but 37% higher than its last 4 quarters average of 17.6
Beam Therapeutics's revenue has plunged by 82% YoY
Efficiency
How efficient is Beam Therapeutics business performance
The ROE has shrunk by 185% YoY but it has increased by 3.5% QoQ
BEAM's ROIC is down by 6% QoQ
The return on sales has declined by 2.7% since the previous quarter
Dividends
What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BEAM.
Financial health
How did Beam Therapeutics financials performed over time
BEAM's quick ratio has surged by 84% since the previous quarter and by 47% year-on-year
BEAM's current ratio has soared by 83% QoQ and by 47% YoY
The debt is 86% less than the equity
BEAM's equity has surged by 53% since the previous quarter and by 23% year-on-year
The company's debt to equity fell by 36% QoQ and by 22% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.